|
Post by sayhey24 on Jan 12, 2018 8:24:56 GMT -5
Rick - you are spot on. For PWDs not on basal Al saw afrezza as the first and only med needed. IMO, he was right. For basal use he always talked about the patch pump. This was prior to Tresiba. Maybe he would now split his view and include Tresiba.
What we do know is the Novo Scientists are on the record saying they have no way to improve on Tresiba. In other words, future basal improvements are not in anyone's near-term pipeline.
For prandial nothing is better than the pancreas and no exogenous insulin can ever do a better job than afrezza. In other words, future prandial developments are not coming either. It was obvious at ADA 2016 nothing was coming, more obvious last year and this year the focus will be CGMs, the cloud and monitoring. The elephant in the room is after monitoring you need to address the problem and the problem is post meal BG spikes. Nothing deals with that better than a healthy pancreas or afrezza.
The issue has always been the fear of the hypo but as VDex has outlined in their paper and what Al said time and again its really really hard to get a hypo with afrezza unless you are using a basal. afrezza will work with the liver like a healthy pancreas. For T2s give them the afrezza as soon as diagnosed, keep them in a non-diabetic range and they have a really great chance of seeing reversal. Thats what I think our new VDex friends in Ohio were trying to say.
|
|
|
Post by sportsrancho on Jan 12, 2018 13:42:11 GMT -5
|
|
|
Post by sportsrancho on Jan 12, 2018 14:40:10 GMT -5
|
|
|
Post by sportsrancho on Jan 12, 2018 14:51:11 GMT -5
|
|
|
Post by sportsrancho on Jan 12, 2018 15:15:03 GMT -5
|
|
|
Post by sportsrancho on Jan 12, 2018 16:50:50 GMT -5
|
|
|
Post by rockstarrick on Jan 12, 2018 17:36:06 GMT -5
Isn’t it incredible that in the past few years a few Innovative Companies have developed what most likely are the best Prandial and Basal Insulin products that may ever be needed for the Treatment of Diabetes until a cure is found. ((((((((((BOOM!!!))))))))))
|
|
|
Post by mannmade on Jan 12, 2018 17:51:04 GMT -5
And yet, where is the recognition for this from the medical community, the insurers and the FDA? Or even the ADA? Who cares about health anyway...? (Sarcasm)
|
|
|
Post by dreamboatcruise on Jan 12, 2018 17:58:47 GMT -5
What we do know is the Novo Scientists are on the record saying they have no way to improve on Tresiba. In other words, future basal improvements are not in anyone's near-term pipeline. For prandial nothing is better than the pancreas and no exogenous insulin can ever do a better job than afrezza. In other words, future prandial developments are not coming either. It was obvious at ADA 2016 nothing was coming, more obvious last year and this year the focus will be CGMs, the cloud and monitoring. The elephant in the room is after monitoring you need to address the problem and the problem is post meal BG spikes. Nothing deals with that better than a healthy pancreas or afrezza. There are researchers trying to develop a BG activated insulin. You might not call it prandial since it would be something that would likely not be dosed with each meal, but if feasible it could replace prandial and basal. I have no real insight into when or even if that could come to reality, other than know it isn't soon.
|
|
|
Post by mannmade on Jan 12, 2018 18:03:51 GMT -5
Yes DBC, I have read about it. Believe it is called "Smart Insulin." I remember reading about it in the past. Think it involves nano technology but have not seen much about it in last year or so.
|
|
|
Post by dreamboatcruise on Jan 12, 2018 18:16:21 GMT -5
Yes DBC, I have read about it. Believe it is called "Smart Insulin." I remember reading about it in the past. Think it involves nano technology but have not seen much about it in last year or so. In general if researchers are throwing around the term "nano technology" for a drug product, I tend to think it may be more hype than reality. Many drugs, even very old ones are within the size range of "nano technology". I'm assuming the "smart insulins" being pursued aren't using technology outside the realm of normal molecular biochemistry. Perhaps they are doing something in a very different way than normal drug development, but I'm skeptical. I've learned to look twice at any investment that claims to be nano tech based.
|
|
|
Post by sellhighdrinklow on Jan 12, 2018 19:42:46 GMT -5
I'm curious how many physicians post on this board.
|
|
|
Post by nylefty on Jan 13, 2018 13:12:56 GMT -5
|
|
|
Post by mango on Jan 13, 2018 14:13:12 GMT -5
What we do know is the Novo Scientists are on the record saying they have no way to improve on Tresiba. In other words, future basal improvements are not in anyone's near-term pipeline. For prandial nothing is better than the pancreas and no exogenous insulin can ever do a better job than afrezza. In other words, future prandial developments are not coming either. It was obvious at ADA 2016 nothing was coming, more obvious last year and this year the focus will be CGMs, the cloud and monitoring. The elephant in the room is after monitoring you need to address the problem and the problem is post meal BG spikes. Nothing deals with that better than a healthy pancreas or afrezza. There are researchers trying to develop a BG activated insulin. You might not call it prandial since it would be something that would likely not be dosed with each meal, but if feasible it could replace prandial and basal. I have no real insight into when or even if that could come to reality, other than know it isn't soon. Merck aquired SmartCells, Inc. in 2010 to pursue a "smart insulin" or glucose-responsive insulin and they completed a three part clinical trial back in 2016 that involved only 74 participants. No study results have been published since the trial's completion. It obviously was a flunk. Others have developed adhesive "micro-needle" patches that have over 100 needles on them that are suppose to be responsive to blood glucose levels, one in particular uses glucose-sensing enzymes. On the other hand, we have Afrezza which is non-invasive and mimics the endogenous secretion of prandial insulin like that of a healthy, non-diabetic pancreas and restores the first-phase insulin response that is loss in PWD, which also in turn restores glucose homeostasis. Can't get any better than that my friend. 😉
|
|
|
Post by careful2invest on Jan 13, 2018 14:24:35 GMT -5
There are researchers trying to develop a BG activated insulin. You might not call it prandial since it would be something that would likely not be dosed with each meal, but if feasible it could replace prandial and basal. I have no real insight into when or even if that could come to reality, other than know it isn't soon. Merck aquired SmartCells, Inc. in 2010 to pursue a "smart insulin" or glucose-responsive insulin and they completed a three part clinical trial back in 2016 that involved only 74 participants. No study results have been published since the trial's completion. It obviously was a flunk. Others have developed adhesive "micro-needle" patches that have over 100 needles on them that are suppose to be responsive to blood glucose levels, one in particular uses glucose-sensing enzymes. On the other hand, we have Afrezza which is non-invasive and mimics the endogenous secretion of prandial insulin like that of a healthy, non-diabetic pancreas and restores the first-phase insulin response that is loss in PWD, which also in turn restores glucose homeostasis. Can't get any better than that my friend. 😉 And there you have it Mango! It can't get any better than that! So why is it that BP and the rest of the medical community still fail to see the obvious and apparent benefits of Afrezza? Afrezza should be what every Endo and Diabetic are talking about. And here we sit, under .50 pre split. A brutal beating!
|
|